News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019